<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2310">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131087</url>
  </required_header>
  <id_info>
    <org_study_id>DF8-CL-20-02</org_study_id>
    <nct_id>NCT05131087</nct_id>
  </id_info>
  <brief_title>A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory Glaucoma</brief_title>
  <official_title>A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New World Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New World Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety, effectiveness, and the surgical performance of CADENCE in patients with&#xD;
      refractory glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CADENCE a single use implantable glaucoma drainage device used for the surgical treatment of&#xD;
      refractory glaucoma. The device is implanted in the eye using an ab-externo approach&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of AEs</measure>
    <time_frame>12 months</time_frame>
    <description>comparison of intra-operative and post-operative adverse events observed to events reported in published literature,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical Experience Evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>An evaluation of the surgical experience using feedback questionnaire to describe specific note of performance characteristics of each implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Change in IOP from Screening to M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOP Lowering Medications</measure>
    <time_frame>12 months</time_frame>
    <description>Change in IOP lowering medications from Screening to M12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Cadence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cadence procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cadence implant</intervention_name>
    <description>CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach</description>
    <arm_group_label>Cadence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  22-80 years of age.&#xD;
&#xD;
          -  moderate to severe refractory glaucoma&#xD;
&#xD;
          -  Able to consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
          -  Intraocular surgery or laser within the last 3 months&#xD;
&#xD;
          -  Ocular infection or inflammation within the last 6 months or currently active&#xD;
&#xD;
          -  Current use of anti-coagulant therapy&#xD;
&#xD;
          -  History of bleeding disorder or coagulopathies&#xD;
&#xD;
          -  Subject plans to undergo any ocular surgery (including cataract surgery) during the&#xD;
             study period&#xD;
&#xD;
          -  History of corneal transplantation&#xD;
&#xD;
          -  History of ICE Syndrome or epithelial ingrowth/downgrowth&#xD;
&#xD;
          -  History of congenital glaucoma&#xD;
&#xD;
          -  Elevated episcleral venous pressure&#xD;
&#xD;
             -. Persistent angle closure-&#xD;
&#xD;
          -  Previous glaucoma filtration surgery- -Presence of conjunctival scarring -&#xD;
&#xD;
          -  neovascular glaucoma&#xD;
&#xD;
          -  AC lens or scleral sutured IOL&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  inability to DC contact lenses&#xD;
&#xD;
          -  Presence of intraocular silicone oil&#xD;
&#xD;
          -  Vitreous in AC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinica Laser y Ultrasonido Ocular de Puebla</name>
      <address>
        <city>Puebla</city>
        <zip>72530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Lazcano, MD</last_name>
      <phone>52 55 1813 6386</phone>
      <email>drlazcano.glaucoma@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aimee Hernandez</last_name>
      <phone>52 55 1813 6386</phone>
      <email>aimeehdz20@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

